Excitement is building around a new weight loss drug, CagriSema, which is expected to surpass the effects of popular drugs ...

THURSDAY, Nov. 7, 2024 (HealthDay News) -- The head of the company that makes the diabetes and obesity drugs Ozempic and ...

Compounded versions of semaglutide, the active ingredient in approved diabetes and obesity drugs Ozempic and Wegovy, have ...

After rising in premarket trading, Novo Nordisk's U.S.-listed shares fell after the market opened Wednesday as its ...

Earlier, Novo Nordisk A/S (NYSE:NVO) petitioned the FDA to ban compounding pharmacies from producing cheaper, unapproved ...

Semaglutide has been on the FDA's shortage list since 2022, which has enabled compounding pharmacies and manufactures to make their own, unapproved versions of the drug. Novo Nordisk in October ...

Novo said supply of Wegovy and Ozempic is in good shape after the drugs were removed from the FDA’s shortage list last week.

Q3 2024 Earnings Call Transcript November 6, 2024 Operator: Good day, and thank you for standing by. Welcome to the Third Quarter 2024 Novo Nordisk A/S Earnings Conference Call. At this time, all ...

The ‘Ozempic drug,’ semaglutide, has been found to reduce moderately severe pain caused by knee osteoarthritis and improve ...

The company's semaglutide injection—better known by the brand names Ozempic and Wegovy—has become well-known for its weight-loss results and ability to manage diabetes. And while there are several ...

The costs for 806 patients with overweight or obesity and heart failure were analyzed in one study. For those patients, the average total medical costs dropped from $29,654 before treatment began to ...

A DAD died after taking a weight loss jab for just a few weeks. Tim Ramsay, from South Australia, wanted to shed some pounds so he could confidently walk his daughter down the aisle. The ...